Table 4.
Effects of Astragalus-Glycyrrhiza polysaccharides on the fatty acid composition of breast muscle.
| Treatments | ||||||
|---|---|---|---|---|---|---|
| Items | CON | ANT | LAG | HAG | SEM | p-Value |
| SFA | ||||||
| C16:0 | 20.25 | 19.49 | 18.93 | 19.01 | 0.21 | 0.078 |
| C18:0 | 9.73 | 9.12 | 8.86 | 8.74 | 0.17 | 0.189 |
| C22:0 | 0.72 a | 0.61 b | 0.56 b | 0.57 b | 0.02 | 0.004 |
| MUFA | ||||||
| C16:1 | 1.27 c | 1.40 b | 1.38 b | 1.54 a | 0.02 | <0.001 |
| C18:1n-9c | 22.25 c | 23.51 ab | 23.02 b | 24.04 a | 0.17 | <0.001 |
| C22:1n-9 | 5.80 | 5.07 | 6.16 | 6.48 | 0.26 | 0.265 |
| C24:1 | 1.30 bc | 1.16 c | 1.55 ab | 1.68 a | 0.07 | 0.017 |
| PUFA | ||||||
| C18:2n-6 | 33.31 b | 35.38 a | 35.04 a | 35.53 a | 0.30 | 0.023 |
| C18:3n-3 | 2.05 c | 2.02 c | 2.66 a | 2.32 b | 0.06 | <0.001 |
| C20:2 | 0.86 b | 0.75 b | 1.12 a | 1.22 a | 0.05 | <0.001 |
| C20:3n-6 | 0.34 | 0.33 | 0.35 | 0.37 | 0.01 | 0.58 |
| C22:6n-3 | 0.60 c | 0.69 c | 1.21 a | 1.00 b | 0.06 | <0.001 |
| Total SFA | 30.70 a | 29.21 ab | 28.35 b | 28.32 b | 0.34 | 0.037 |
| Total MUFA | 30.62 c | 31.13 bc | 32.10 b | 33.73 a | 0.33 | 0.001 |
| Total PUFA | 37.15 b | 39.15 a | 40.32 a | 40.43 a | 0.36 | 0.001 |
| PUFA/SFA | 1.22 b | 1.35 a | 1.43 a | 1.43 a | 0.03 | 0.004 |
| n-6/n-3 | 57.83 a | 54.42 a | 29.82 b | 36.80 b | 2.99 | <0.001 |
Note: The data were shown as means and standard error (SEM) (n = 6). The different lowercase letters in the same rows indicate significant difference (p < 0.05), while the same or without lowercase letters in the same rows indicate insignificant difference (p > 0.05). SFA: saturated fatty acid; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acid; CON: basal diet group; ANT: supplement with 500 mg/kg oxytetracycline calcium; LAG: supplement with 150 mg/kg Astragalus polysaccharides and 75 mg/kg Glycyrrhiza polysaccharides; HAG: supplement with 300 mg/kg Astragalus polysaccharides and 150 mg/kg Glycyrrhiza polysaccharides.